Puberty induction with recombinant gonadotropin: What impact on future fertility?

The document discusses the impact of using recombinant gonadotropins for puberty induction in individuals with congenital hypogonadotropic hypogonadism (CHH), a condition characterized by inadequate secretion of LH and FSH. Historically treated with testosterone injections, recent studies over the past 20 years highlight the benefits of recombinant gonadotropins in promoting future fertility. These treatments facilitate steroidogenesis and spermatogenesis, leading to physiological puberty, including genital maturation and increased testicular volume. However, testicular volume often remains pre-pubertal, particularly in patients with bilateral cryptorchidism, though spermatogenesis is achieved in most cases after 2 years. The study emphasizes the need for larger randomized trials to optimize treatment approaches.